GlassScriptPhysician profile
Kevin Edward Shinal
NPI 1568430197
$205,287.70
in general payments reported to CMS, 2019-2025
21 companies · $18K in 2025
The $18K reported for 2025 was more than what 96% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27K · 2020: $27K · 2021: $22K · 2022: $34K · 2023: $35K · 2024: $43K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $86K · Consulting Fee: $5,500 · Food and Beverage: $2,414 · Travel and Lodging: $1,740.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $86,070.00 |
| Consulting Fee | $5,500.00 |
| Food and Beverage | $2,414.16 |
| Travel and Lodging | $1,739.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $172,702.68 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $24,241.14 | 2019-2025 | Jardiance |
| Eli Lilly and Company | $7,199.66 | 2024 | Jardiance |
| Pfizer INC. | $159.97 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $142.96 | 2019-2025 | |
| Amgen INC. | $137.18 | 2021 | |
| Janssen Pharmaceuticals, INC | $103.56 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $102.76 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $81.65 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $76.75 | 2019 | |
| Medtronic, INC. | $75.63 | 2024-2025 | Micra, Linq II |
| Merck Sharp & Dohme LLC | $47.81 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $33.71 | 2019-2023 | Lifevest |
| Biotronik INC. | $29.05 | 2019-2021 | |
| Heartflow, INC. | $28.73 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $26.81 | 2019-2023 | Farxiga |
| Amarin Pharma, INC. | $24.09 | 2019 | |
| Tactile Systems Technology INC | $21.11 | 2025 | Nimbl, Flexitouch Plus |
| Esperion Therapeutics, INC. | $20.03 | 2024 | Nexletol |
| Boston Scientific Corporation | $18.14 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $14.28 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Shinal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.